Virpax CMO Jeffrey Gudin resigns as officer, continues as director; receives $81,900 severance

Virpax Pharmaceuticals, Inc.

Jeffrey Gudin resigned as Chief Medical Officer and EVP on May 2, 2024; no disagreement cited.
Separation agreement provides $81,900 paid semi-monthly over six months plus COBRA reimbursement.
Unvested options for 5,358 shares will continue to vest; total options for 20,616 shares.
Gudin remains a Class III Director of the company.
Agreement includes general release and non-disparagement clauses.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey Gudin

Chief Medical Officer and Executive Vice President

Virpax Pharmaceuticals, Inc.

Effective: 2024-05-02
Filed: May 2, 2024, 7:59 PM ET

On May 2, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) entered into a Separation Agreement and Release, dated May 2, 2024 (the “Separation Agreement”), with Jeffrey Gudin, MD pursuant to which Dr. Gudin resigned from his positions of Chief Medical Officer and Executive Vice President of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Gudin resigned as Chief Medical Officer and Executive Vice President at Virpax Pharmaceuticals, Inc..

Action: resigned
Role: Chief Medical Officer and Executive Vice President

Exact text from the filing

On May 2, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) entered into a Separation Agreement and Release, dated May 2, 2024 (the “Separation Agreement”), with Jeffrey Gudin, MD pursuant to which Dr. Gudin resigned from his positions of Chief Medical Officer and Executive Vice President of the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001213900-24-039098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.